Cat. #162160
A549 LIMD1 KO Cas9 cell line
Cat. #: 162160
Availability: 8-10 weeks
Organism: Human
Tissue: Lung
Model: Genetically modified cell line; Knock out
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Tyson Sharp
Institute: Queen Mary University of London
Primary Citation: Kathryn Davidson et. al. 2021. Cell Death Dis. 12(11): 1075. PMID: 34764236
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: A549 LIMD1 KO Cas9 cell line
- Cancers detailed: Lung Cancer
- Research fields: Cancer
- Parental cell: A549 cell line
- Organism: Human
- Gender: Male
- Tissue: Lung
- Donor: White, 58-year-old male with lung cancer
- Morphology: Epithelial
- Growth properties: Adherent
- Model: Genetically modified cell line; Knock out
- Crispr: Yes
- Description: A549 lung adenocarcinoma line knocked-out for the tumour suppressor gene LIMD1, which is commonly lost as an early event in lung oncogenesis. This gene encodes a scaffold protein suppressesing tumorigenesis via a number of different mechanisms. This line has been used to test drugs in LIMD1-deficient lung cancers, both in vitro an in vivo. When inoculated into NOD/SCID mice subcutaneously, CRISPR-Cas9-generated LUAD A549 LIMD1+/+ and LIMD1?/? cells generate LIMD1+/+ and LIMD1?/? tumours, respectively.
Handling
- Format: Frozen
- Growth medium: DMEM medium supplemented with 10% FCS and 1% penicillin/streptomycin solution
- Temperature: 37° C
- Atmosphere: 5% CO2
- Shipping conditions: Dry ice
- Cultured in antibiotics: Yes
- Mycoplasma free: Yes
Related Tools
- Related tools: A549 LIMD1 WT Cas9 cell line
References
- Kathryn Davidson et. al. 2021. Cell Death Dis. 12(11): 1075. PMID: 34764236
